Clinical trial
Eight-Weeks Of Treatment With Talnetant In Subjects With Irritable Bowel…
NCT00101985 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00101985 |
|---|---|
| Title | Eight-Weeks Of Treatment With Talnetant In Subjects With Irritable Bowel Syndrome (IBS) |
| Official title | An Eight-week, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate Efficacy and Safety of Talnetant in Subjects With Irritable Bowel Syndrome |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Irritable Colon |
| Intervention type | Drug |
| Interventions | talnetant |
| Enrollment | 741 |
| Start date | Oct 1, 2004 |
| Primary completion | Jul 1, 2005 |
| Completion | Jul 1, 2005 |
| First posted | Jan 19, 2005 |
| Last update posted | Apr 13, 2015 |
| Countries | Australia, Canada, France, Germany, Netherlands, South Africa, Spain, Sweden, United Kingdom, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: